ADMA Biologics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 33.17%

ADMA Biologics, Inc. EBIT Margin is 33.17% for the Trailing 12 Months (TTM) ending March 31, 2025, a 387.06% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • ADMA Biologics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 6.81%, a -148.23% change year over year.
  • ADMA Biologics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -14.12%, a -79.59% change year over year.
  • ADMA Biologics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -69.18%, a -46.73% change year over year.
  • ADMA Biologics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -129.85%, a 5.62% change year over year.
Key Data
Date EBIT Margin EBITDA Margin Net Income Margin EBT Margin